Nektar Therapeutics (NASDAQ: NKTR) on Tuesday, plunged -9.35% from the previous trading day, before settling in for the closing price of $0.93. Within the past 52 weeks, NKTR’s price has moved between $0.63 and $1.93.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -2.93% over the past five years. The company achieved an average annual earnings per share of 50.60%. With a float of $177.74 million, this company’s outstanding shares have now reached $184.46 million.
Let’s look at the performance matrix of the company that is accounted for 137 employees. In terms of profitability, gross margin is 67.8%, operating margin of -145.96%, and the pretax margin is -180.71%.
Nektar Therapeutics (NKTR) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Nektar Therapeutics is 3.64%, while institutional ownership is 70.10%. The most recent insider transaction that took place on Feb 19 ’25, was worth 10,403. In this transaction Chief R&D Officer of this company sold 10,300 shares at a rate of $1.01, taking the stock ownership to the 316,604 shares. Before that another transaction happened on Feb 19 ’25, when Company’s Chief Legal Officer sold 11,040 for $1.01, making the entire transaction worth $11,150. This insider now owns 324,292 shares in total.
Nektar Therapeutics (NKTR) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.21 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 50.60% per share during the next fiscal year.
Nektar Therapeutics (NASDAQ: NKTR) Trading Performance Indicators
Nektar Therapeutics (NKTR) is currently performing well based on its current performance indicators. A quick ratio of 4.24 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.67.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.84, a number that is poised to hit -0.14 in the next quarter and is forecasted to reach -0.77 in one year’s time.
Technical Analysis of Nektar Therapeutics (NKTR)
Nektar Therapeutics (NASDAQ: NKTR) saw its 5-day average volume 2.4 million, a negative change from its year-to-date volume of 2.43 million. As of the previous 9 days, the stock’s Stochastic %D was 60.78%. Additionally, its Average True Range was 0.09.
During the past 100 days, Nektar Therapeutics’s (NKTR) raw stochastic average was set at 23.21%, which indicates a significant decrease from 45.35% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 129.83% in the past 14 days, which was higher than the 78.80% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.9182, while its 200-day Moving Average is $1.2033. Nevertheless, the first resistance level for the watch stands at $0.9180 in the near term. At $0.9911, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.0340. If the price goes on to break the first support level at $0.8020, it is likely to go to the next support level at $0.7591. Assuming the price breaks the second support level, the third support level stands at $0.6860.
Nektar Therapeutics (NASDAQ: NKTR) Key Stats
Market capitalization of the company is 155.87 million based on 184,458K outstanding shares. Right now, sales total 90,120 K and income totals -276,060 K. The company made 24,120 K in profit during its latest quarter, and -37,060 K in sales during its previous quarter.
